Clinical Trial Update: ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Failure [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for ALP-1 given via continuous intravenous infusion aimed at maintaining stability in advanced heart failure; the study is not yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Heart Failure
• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• ALP-1

Snippet

Sponsor: Biopeutics Co., Ltd | Conditions: End Stage Cardiac Failure, HFrEF - Heart Failure With Reduced Ejection Fraction | Phase 3 | Status: NOT_YET_RECRUITING